Clinical Cancer Research· 2019Q1
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
- 1,165citations
- Q1SCImago
- 2019year
Short summary
Pembrolizumab gained FDA approval on May 23, 2017, for unresectable/metastatic MSI-H/dMMR solid tumors and colorectal cancers, marking the first biomarker-based cancer treatment approval.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pathology and Forensic Medicine
Pathology and Forensic MedicineMedicine